FORMULATING
THE FUTURE
OF BIOLOGICS™.

A better way of doing things, subcutaneously.  

By reengineering how medicines get to patients, we are untethering patients from the burdens and limitations associated with traditional biologic administration.

We challenged what is possible. We are leading the revolution.

→ About Us

Leading the revolution with smarter medicine delivery.

Revolutionizing the delivery of biologic therapies through our hyper concentration microparticle platform technology, Hypercon™.

We are expanding new frontiers to give our partners, and their patients, smarter medicine delivery to better support their patients on their treatment journeys. 

OUR PURPOSE DRIVES OUR PASSION TO HELP PATIENTS GET THE MEDICINES THEY NEED, WHEN THEY NEED THEM.

OUR PURPOSE DRIVES OUR PASSION TO HELP PATIENTS GET THE MEDICINES THEY NEED, WHEN THEY NEED THEM.

Featured
Elektrofi Announces Oversubscribed $112.25 Million Series C Financing to Establish Commercial-Scale GMP Manufacturing Capacity & Accelerate Clinical Development Across its Growing Portfolio

Proceeds will be used, in part, to establish Ph3 and commercial-scale GMP manufacturing capacity that will accelerate clinical development and provide global support for a growing portfolio of programs with existing and emerging partners.

Read More →
Elektrofi and Janssen Biotech Enter Worldwide Collaboration and License Agreement to Exclusively Develop up to Five Programs Utilizing Elektrofi’s Formulation Technology  

Elektrofi and Janssen Biotech Enter Worldwide Collaboration and License Agreement to Exclusively Develop up to Five Programs Utilizing Elektrofi’s Formulation Technology

Read More →
Elektrofi and Lilly Enter Multi-Target Research Collaboration and License Agreement

BOSTON, October 24, 2023 (GLOBE NEWSWIRE)

Elektrofi, Inc., a biopharmaceutical formulation technology company focused on leveraging strategic partnerships to revolutionize the delivery of biologic therapies, announced today that it has entered a multi-target research collaboration and license agreement with Eli Lilly and Company to develop next-generation medicines that can be delivered subcutaneously.

Read More →